The second edition of the Drug Repurposing Venture Challenge has officially started. From June to October 2026, four ambitious teams will work on further developing innovative drug repurposing concepts and translating them into promising venture plans.

During the first bootcamp, RARE-NL introduced the basics of the regulatory and reimbursement landscape for repurposing. But how can this be done in a socially responsible way? That was the focus of day 2: practical ways to retain control over your company, ensure transparency, and support patient access in the Netherlands, Europe and worldwide.

The Venture Challenge

During the programme, teams are supported in developing a venture plan in which a scientific breakthrough in drug repurposing is translated into a solid business case. The focus is not only on scientific and commercial feasibility, but also on socially responsible implementation and accessibility for patients.

The Venture Challenge consists of two intensive three-day bootcamps, complemented by coaching sessions with experts from the Life Sciences sector, investors and experienced entrepreneurs.

Throughout the programme, the teams work on value propositions, validation strategies, business development, and writing and pitching a venture plan. The challenge concludes with a final day on 7 October and an award ceremony on 29 October 2026 during the FAST event 2026. The winning team will receive €20,000 to further develop its drug repurposing concept.

Want to learn more about the teams? Read more here:
https://www.fast.nl/nieuws/drug-repurposing-venture-challenge-2026-van-start-vier-teams-werken-aan-innovatieve-toepassingen/